Drug Information

Drug General Information
Drug ID
D0B6QZ
Former ID
DIB009169
Drug Name
AVE-2268
Indication Diabetes [ICD9: 253.5, 588.1; ICD10:E23.2, N25.1] Phase 2 [521866]
Company
Aventis SA
Target and Pathway
Target(s) SLGT2 Target Info Modulator [529915]
Reactome Hexose transport
Na+-dependent glucose transporters
Inositol transporters
WikiPathways NRF2 pathway
Nuclear Receptors Meta-Pathway
Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds
References
Ref 521866ClinicalTrials.gov (NCT00361738) Dose-Ranging Study Evaluating AVE2268 in Patients With Type 2 Diabetes Not Adequately Controlled by a Metformin Treatment. U.S. National Institutes of Health.
Ref 529915Effects of AVE2268, a substituted glycopyranoside, on urinary glucose excretion and blood glucose in mice and rats. Arzneimittelforschung. 2008;58(11):574-80.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.